TegoScience Inc. (KOSDAQ:191420)
7,180.00
+670.00 (10.29%)
At close: Jun 29, 2026
TegoScience Revenue
TegoScience had revenue of 1.20B KRW in the quarter ending March 31, 2026, a decrease of -8.69%. This brings the company's revenue in the last twelve months to 5.83B, down -14.28% year-over-year. In the year 2025, TegoScience had annual revenue of 5.94B, down -12.11%.
Revenue (ttm)
5.83B
Revenue Growth
-14.28%
P/S Ratio
9.87
Revenue / Employee
n/a
Employees
42
Market Cap
57.49B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.94B | -818.34M | -12.11% |
| Dec 31, 2024 | 6.76B | -1.01B | -13.04% |
| Dec 31, 2023 | 7.77B | 94.02M | 1.22% |
| Dec 31, 2022 | 7.68B | -621.23M | -7.49% |
| Dec 31, 2021 | 8.30B | -489.49M | -5.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| KoBioLabs | 71.21B |
| Psomagen | 60.70B |
| J2KBIO | 36.82B |
| Naturalendo Tech | 21.69B |
| PanGen Biotech | 13.71B |
| QuadMedicine | 9.78B |
| EyeGene | 4.02B |
| Aptamer Sciences | 1.08B |